Clin Res Cardiol (2022). https://doi.org/10.1007/s00392-022-02002-5 |
||
Results of Transcatheter Aortic Valve Implantation in Patients with Left Ventricular Assist Device Support | ||
P. Lanmüller1, A. Unbehaun1, J.-J. Eulert-Grehn1, C. Klein2, M. Hommel3, M. Kofler1, J. Kempfert1, C. Hörmandinger1, F. Kaufmann1, P. Stawowy2, S. Dreysse2, J. Mulzer1, M. Müller1, V. Falk4, F. Schönrath1, E. Potapov1, I. A. Just2 | ||
1Klinik für Herz-, Thorax- und Gefäßchirurgie, Deutsches Herzzentrum Berlin, Berlin; 2Klinik für Innere Medizin - Kardiologie, Deutsches Herzzentrum Berlin, Berlin; 3Deutsches Herzzentrum Berlin, Berlin; 4Klinik für kardiovaskuläre Chirurgie, Charité - Universitätsmedizin Berlin, Berlin; | ||
Objectives: Approximately 15% of patients on left ventricular assist device (LVAD) support develop severe aortic regurgitation (AR). Since patients on LVAD support are considered at high risk for reoperation, the interventional approach is becoming increasingly important in this patient cohort. Methods: We conducted a retrospective analysis to evaluate the outcomes of patients on LVAD support, who underwent transcatheter aortic valve implantation (TAVI) at our institution between January 1st, 2016 and December 1st, 2020. Results: During the investigational period, 18 TAVI were performed in LVAD patients at our institution. Mean age was 62.4 (±9.6) years and 72.2% were male. Before LVAD implantation, no or mild AR was pre-existing. The time from LVAD implantation to severe AR ranged from 0.5 to 9.5 years. Conclusion: TAVI is a safe and feasible way to treat severe aortic regurgitation in patients on LVAD support. |
||
https://dgk.org/kongress_programme/jt2022/aP1872.html |